Societal CDMO, Inc. (SCTL)
NASDAQ: SCTL · IEX Real-Time Price · USD
1.090
0.00 (0.00%)
At close: Mar 27, 2024, 4:00 PM
1.080
-0.010 (-0.92%)
After-hours: Mar 27, 2024, 7:39 PM EDT
Company Description
Societal CDMO, Inc., a contract development and manufacturing organization, engages in the research and development, manufacturing, and packaging for various therapeutic dosage forms primarily in the small molecules in the United States and internationally.
It provides therapeutic development, end-to-end regulatory support, clinical and commercial manufacturing, aseptic fill/finish, lyophilization, packaging and logistics services to the global pharmaceutical market.
The company was formerly known as Recro Pharma, Inc. and changed its name to Societal CDMO, Inc. in March 2022.
Societal CDMO, Inc. was incorporated in 2007 and is based in Exton, Pennsylvania.
Societal CDMO, Inc.
Country | United States |
Founded | 2007 |
IPO Date | Mar 7, 2014 |
Industry | Drug Manufacturers - Specialty & Generic |
Sector | Healthcare |
Employees | 258 |
CEO | J. David Enloe Jr. |
Contact Details
Address: 1 E. Uwchlan Ave, Suite 112 Exton, Pennsylvania 19341 United States | |
Phone | 770-534-8239 |
Website | societalcdmo.com |
Stock Details
Ticker Symbol | SCTL |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001588972 |
CUSIP Number | 75629F109 |
ISIN Number | US75629F1093 |
Employer ID | 26-1523233 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Wayne B. Weisman J.D. | Executive Chairman of the Board |
J. David Enloe Jr. | President, Chief Executive Officer and Director |
Ryan D. Lake CPA | Senior Vice President and Chief Financial Officer |
Marshall Rizzo M.B.A. | Senior Vice President and Chief Operating Officer |
Richard Sidwell Ph.D. | Senior Vice President and Chief Scientific Officer |
Cristin Grove | Vice President of Sales |
Erica Raether M.A. | Senior Vice President and Chief People Officer |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Mar 22, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
Mar 22, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
Mar 22, 2024 | 10-K | Annual Report |
Mar 18, 2024 | SC 14D9/A | Filing |
Mar 18, 2024 | SC TO-T/A | Filing |
Mar 15, 2024 | 8-K | Current Report |
Mar 11, 2024 | SC 14D9 | Filing |
Mar 11, 2024 | SC TO-T | Filing |
Mar 6, 2024 | SC 13D | General statement of acquisition of beneficial ownership |
Feb 29, 2024 | SC14D9C | Filing |